What is Lifesci Capital’s Estimate for ELVN Q3 Earnings?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) – Research analysts at Lifesci Capital raised their Q3 2025 earnings per share (EPS) estimates for shares of Enliven Therapeutics in a report issued on Thursday, August 14th. Lifesci Capital analyst S. Slutsky now expects that the company will earn ($0.45) per share for the quarter, up from their previous forecast of ($0.52). The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.95) per share. Lifesci Capital also issued estimates for Enliven Therapeutics’ Q4 2025 earnings at ($0.47) EPS and FY2025 earnings at ($1.96) EPS.

Several other equities research analysts have also commented on ELVN. The Goldman Sachs Group began coverage on Enliven Therapeutics in a research note on Monday, June 16th. They issued a “buy” rating and a $37.00 price objective for the company. Robert W. Baird upped their target price on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday, June 16th. HC Wainwright upped their target price on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, July 2nd. Finally, Jones Trading dropped their target price on shares of Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating for the company in a report on Friday, May 16th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Enliven Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $41.20.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $20.22 on Monday. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -10.11 and a beta of 0.93. Enliven Therapeutics has a one year low of $13.30 and a one year high of $30.03. The business has a fifty day moving average price of $20.67 and a 200-day moving average price of $19.90.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.04.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ELVN. Tower Research Capital LLC TRC boosted its holdings in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after purchasing an additional 1,114 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Enliven Therapeutics by 3,058.1% during the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock valued at $53,000 after buying an additional 2,630 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Enliven Therapeutics during the 1st quarter valued at about $60,000. BNP Paribas Financial Markets raised its position in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after buying an additional 930 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of Enliven Therapeutics by 194.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after buying an additional 3,490 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

Insider Activity

In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $20.34, for a total transaction of $135,606.78. Following the completion of the transaction, the chief operating officer owned 303,309 shares of the company’s stock, valued at $6,169,305.06. This represents a 2.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Samuel Kintz sold 12,500 shares of the stock in a transaction dated Thursday, July 17th. The shares were sold at an average price of $22.52, for a total transaction of $281,500.00. Following the transaction, the chief executive officer directly owned 940,392 shares of the company’s stock, valued at $21,177,627.84. This trade represents a 1.31% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 95,751 shares of company stock worth $2,004,325. 25.90% of the stock is currently owned by corporate insiders.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.